{
  "id": "cluster_3_doc2",
  "content": "Policy memo 2024-87 outlines new prior authorization requirements for advanced genetic therapies in Northern Nevada. Effective May 1st, all GT-204 series treatments require secondary review by the regional genetics panel. Exception process available for patients with documentation of rapid disease progression.",
  "metadata": {
    "format": "policy_document"
  }
}